Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426127 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer
A Phase 2 study, sponsored by University of Iowa.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00426127 is a Phase 2 study that was terminated before completion, run by University of Iowa. The registered enrollment target is 2 participants.
The verdict
NCT00426127, a Phase 2 study, was terminated before completion, sponsored by University of Iowa.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of the treatment combination of the commercially available chemotherapy drugs, docetaxel and liposomal doxorubicin, and a blood thinner Enoxaparin on pancreatic cancer. The main goal of the study is to find out if this combination chemotherapy and enoxaparin increases the number of individuals whose tumors shrink.
Interventions
- DRUG Docetaxel
- DRUG Liposomal Doxorubicin
- DRUG Enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00426127
The ClinicalTrials.gov registry entry for NCT00426127 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Iowa, which has 228 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00426127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00426127 about?
NCT00426127 is a clinical study titled "Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer". The purpose of this study is to assess the effects of the treatment combination of the commercially available chemotherapy drugs, docetaxel and liposomal doxorubicin, and a blood thinner Enoxaparin on pancreatic cancer. The main goal of the study is to find out if this combination chemotherapy and e...
What is the current status of trial NCT00426127?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2006-11. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00426127?
The interventions under investigation include: Docetaxel (DRUG), Liposomal Doxorubicin (DRUG), Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT00426127?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.